Myeloma News and Research

RSS

Studies reveal the promise of newly engineered bispecific antibodies against tumor cells

Three studies - one each in Science, Science Translational Medicine, and Science Immunology - reveal the promise of newly engineered bispecific antibodies, including by demonstrating their power against previously inaccessible tumor cell targets for the first time, in two cases.

2 Mar 2021

CAR T-cell therapy produces deep, sustained remissions in patients with relapsed myeloma

In a major advance in the treatment of multiple myeloma, a CAR T-cell therapy has generated deep, sustained remissions in patients who had relapsed from several previous therapies, an international clinical trial has found.

24 Feb 2021

Benjamin L. Ebert receives Sjöberg Prize for breakthrough research on blood cancer

Benjamin L. Ebert, USA, receives this year's Sjöberg Prize, worth one million US dollars, for his research into how lenalidomide works as a treatment for blood cancer.

15 Feb 2021

Immunomodulatory drugs improve the success rate of cancer therapies

Immunomodulatory drugs, including the Contergan derivatives lenalidomide and pomalidomide, have significantly improved the therapy of hematologic malignancies such as multiple myeloma.

15 Feb 2021

Study reveals mechanisms behind sensitivity of multiple myeloma cells to EZH2 inhibition

Researchers from Uppsala University show in a new study that inhibition of the protein EZH2 can reduce the growth of cancer cells in the blood cancer multiple myeloma.

13 Feb 2021

Study provides new insights into the mechanism of bone marrow tissue

Imagine a day when clinicians treating people with blood diseases such as leukemia or multiple myeloma can send in requests for laboratories to custom-produce specific types of blood cells to replace those affected by the disease.

10 Feb 2021

DSMB recommends continuation of Phase 2/3 study of opaganib for severe COVID-19

RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced that the independent Data Safety Monitoring Board (DSMB) for the global Phase 2/3 study of opaganib in patients with severe COVID-19, unanimously recommended to continue the study following a pre-scheduled futility review of unblinded efficacy data from the first 135 patients treated in the study and safety data from the first 175 patients.

30 Jan 2021

Two enzymes fuel transition from pre-cancer stem cells to leukemia stem cells

Since stem cells can continually self-regenerate, making more stem cells, and differentiate into many different specialized cell types, they play an important role in our development and health.

26 Jan 2021

Whole body imaging detects more myeloma-defining disease, allows treatment to be initiated earlier

Researchers from King's College London have shown that whole body magnetic resonance imaging (WBMRI) not only detects more myeloma-defining disease than positron emission tomography/computed tomography (PET/CT) with 18F-fluorodeoxyglucose (FDG) but that it also allows critical treatment to be initiated earlier.

21 Jan 2021

Designer DNA agent reduces myeloma stem cell abundance, lowers disease burden in mice

Many patients with multiple myeloma, a type of blood cancer, eventually develop resistance to one treatment after another. That's in part because cancer stem cells drive the disease -- cells that continually self-renew. If a therapy can't completely destroy these malignant stem cells, the cancer is likely to keep coming back.

20 Jan 2021

Seniors face crushing drug costs as Congress stalls on capping Medicare out-of-pockets

Sharon Clark is able to get her life-sustaining cancer drug, Pomalyst — priced at more than $18,000 for a 28-day supply — only because of the generosity of patient assistance foundations.

4 Jan 2021

P2 COVID-19 study shows no material safety differences between opaganib and control arms

Preliminary data from the non-powered U.S. Phase 2 study of 40 hospitalized patients shows that orally-administered opaganib was safe, with no material safety differences between opaganib and control arms.

4 Jan 2021

Phase 2/3 COVID-19 study evaluates safety, potential identification of preliminary efficacy signals

Top-line data from the 270-patient global Phase 2/3 COVID-19 study expected Q1/2021. Top-line data from the 40-patient U.S. Phase 2 study of opaganib in severe COVID-19 expected in the coming days; this non-powered study was designed to evaluate safety and potential identification of preliminary efficacy signals in support of the global Phase 2/3 study of opaganib.

23 Dec 2020

Landmark study finds how often cancer patients develop osteonecrosis of the jaw

A landmark study by researchers from the SWOG Cancer Research Network, a cancer clinical trials group funded by the National Cancer Institute, part of the National Institutes of Health, has found that 2.8 percent of patients on average develop osteonecrosis of the jaw, or ONJ, within three years of starting a common treatment for cancer that has spread to the bone.

17 Dec 2020

Ohio State receives $10 million gift to establish new myeloma research center

The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute has received a $10 million gift from the Paula and Rodger Riney Foundation to establish the Riney Family Foundation Myeloma Center for Advanced Research Excellence.

17 Dec 2020

RedHill Biopharma announces promising preliminary results from opaganib study

TEL AVIV, Israel and RALEIGH, NC, December 15, 2020, RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced promising preliminary results from a preclinical study with opaganib.

15 Dec 2020

Study highlights previously unknown mechanisms involved in myeloma resistance

A group of researchers led by Maximillian Merz, MD, Assistant Professor of Oncology with the Myeloma team at Roswell Park Comprehensive Cancer Center, conducted the first prospective clinical trial investigating spatial heterogeneity in patients with either relapsed/refractory or newly diagnosed multiple myeloma.

7 Dec 2020

Study finds CAR T cell therapy as effective as first-line treatment for high-risk large B-cell lymphoma

A study led by researchers at The University of Texas MD Anderson Cancer Center found that axi-cel, an autologous anti-CD19 chimeric antigen receptor (CAR) T cell therapy, is a safe and effective first-line therapy for patients with high-risk large B-cell lymphoma (LBCL), a group with an urgent need for new and effective treatments.

7 Dec 2020

Clinical investigators present abstracts on hematological malignancies at ASH Annual Meeting and Exposition

Clinical investigators from Hackensack Meridian Health John Theurer Cancer Center (JTCC), a member of the Georgetown Lombardi Comprehensive Cancer Center consortium, are to present updates on treatment advances in multiple myeloma (MM), mantle cell lymphoma (MCL), and other types of B-cell lymphoma (BCL) as well as leukemia at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, to be held virtually from December 5-8, 2020.

7 Dec 2020

More than 40 Dana-Farber studies to be presented at the virtual 62nd ASH Annual Meeting

Dana-Farber Cancer Institute researchers will present more than 40 research studies at the virtual 62nd American Society of Hematology Annual Meeting on December 5-8, including two studies that were selected for inclusion in the official press program.

1 Dec 2020

Myeloma News and Research

Studies reveal the promise of newly engineered bispecific antibodies against tumor cells

CAR T-cell therapy produces deep, sustained remissions in patients with relapsed myeloma

Benjamin L. Ebert receives Sjöberg Prize for breakthrough research on blood cancer

Immunomodulatory drugs improve the success rate of cancer therapies

Study reveals mechanisms behind sensitivity of multiple myeloma cells to EZH2 inhibition

Study provides new insights into the mechanism of bone marrow tissue

DSMB recommends continuation of Phase 2/3 study of opaganib for severe COVID-19

Two enzymes fuel transition from pre-cancer stem cells to leukemia stem cells

Whole body imaging detects more myeloma-defining disease, allows treatment to be initiated earlier

Designer DNA agent reduces myeloma stem cell abundance, lowers disease burden in mice

Seniors face crushing drug costs as Congress stalls on capping Medicare out-of-pockets

P2 COVID-19 study shows no material safety differences between opaganib and control arms

Phase 2/3 COVID-19 study evaluates safety, potential identification of preliminary efficacy signals

Landmark study finds how often cancer patients develop osteonecrosis of the jaw

Ohio State receives $10 million gift to establish new myeloma research center

RedHill Biopharma announces promising preliminary results from opaganib study

Study highlights previously unknown mechanisms involved in myeloma resistance

Study finds CAR T cell therapy as effective as first-line treatment for high-risk large B-cell lymphoma

Clinical investigators present abstracts on hematological malignancies at ASH Annual Meeting and Exposition

More than 40 Dana-Farber studies to be presented at the virtual 62nd ASH Annual Meeting

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News